X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The POCare Platform has been designed by Orgenesis to enable hospitals and healthcare facilities globally to develop, optimize and manufacture cell and gene therapies throughout a POC Network of global healthcare facilities.
Lead Product(s): Autologous mesenchymal stem cells infected oncolytic virus
Therapeutic Area: Oncology Product Name: Celyvir
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Hospital Infantil Universitario Niño Jesús
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 11, 2021
Details:
Following closing of the Transaction, Orgenesis plans to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in international markets as well.
Lead Product(s): Autologous pancreatic islets cells
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Kyslecel
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Koligo Therapeutics
Deal Size: $16.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2020
Details:
The agreement is part of the Orgenesis strategy of growing and expanding the POCare Network. The first collaboration under the agreement will focus on the clinical development of CAR-T and whole cell-based vaccine platform for use in cancer immunotherapies.
Lead Product(s): CAR-T cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Educell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 14, 2020
Details:
Orgenesis has entered into a preliminary, non-binding term sheet with Leidos to develop and potentially obtain FDA marketing approval of Orgenesis’ Ranpirnase for the systemic treatment of patients suffering with SARS-CoV-2 the virus that causes COVID-19.
Lead Product(s): Ranpirnase
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leidos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 24, 2020
Details:
Clinical study will be undertaken with goal of utilizing and validating a number of Orgenesis’ proprietary POCare Technologies, including an automated cell culturing system for the generation and expansion tumor infiltrating lymphocytes for use in adoptive T-cell therapies.
Lead Product(s): Tumor infiltrating lymphocytes
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Edith Wolfson Medical Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2020
Details:
Orgenesis and TamirBio plan to combine ranpirnase with Bioxomes, which have shown the ability to fuse with cell membranes and deliver an intracellular cargo, in a similar manner to natural exosomes.
Lead Product(s): Ranpirnase
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Tamir Biotechnology
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
